ArticleEndocrine pathology2015
The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Article in Endocrine pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it, 227 citations in OpenAlex.
- The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis.Endocrine · 2023Pooled it
- Clinical characteristics and prognostic outcomes of silent corticotroph versus gonadotroph adenomas: A 603-case single-center cohort study.Neurosurgical review · 2026Article
- Constant ovulation during oral contraceptive treatment: Follicle-stimulating hormone-secreting pituitary adenoma case report and literature review.Journal of family medicine and primary care · 2026Article
- Emergence of NEC features in corticotroph PitNETs: primary tumor, radiation-induced transformation, or metastasis?Brain tumor pathology · 2026Article
- Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside.Endocrine-related cancer · 2026Review
- Article
- Characterization of the secretory profile of gonadotroph pituitary tumors.Journal of endocrinological investigation · 2026Article
- Oxidative Phosphorylation in Silent Pituitary Adenomas: A Multiomics Perspective.International journal of endocrinology · 2026Article
- Mast cells act as pro-angiogenic and pro-tumorigenic players in pituitary gonadotroph tumors.Neuro-oncology · 2026Article
- Corticotroph Tumour Type Influences Clinical Behaviour in Patients With Nonfunctioning Pituitary Neuroendocrine Tumours.Endocrinology, diabetes & metabolism · 2026Article
- Integrating single-cell and bulk RNA sequencing data reveals RGS4 as a functional driver in a proliferative subgroup of SF-1 lineage PitNETs.Frontiers in cell and developmental biology · 2026Article
- Pathological Classification and Clinical Characteristics of Growth Hormone-Secreting PitNETs.Neuroendocrinology · 2026Article
- Challenges in the Management of Silent Lactotroph Pituitary Adenoma.JCEM case reports · 2025Article
- Status of temozolomide use without insurance coverage in patients with aggressive pituitary neuroendocrine tumors.Endocrine journal · 2025Article
- SSTR2 expression in neoplastic and normal anterior pituitary is impacted by age, sex, and hormonal status.Journal of neuropathology and experimental neurology · 2025Article
- Clinical integration and application of the 2022 WHO pituitary tumor classification.Neuro-oncology advances · 2025Article
- Transcription factor-based classification of pituitary adenomas / PitNETs: a comparative analysis and clinical implications across WHO 2004, 2017 and 2022 in 921 cases.Acta neuropathologica communications · 2025Article
- Cell Lineage-Specific Differences in Clinical Behavior of Non-Functioning Pituitary Adenomas.The Journal of clinical endocrinology and metabolism · 2025Article
- Radiomics based on preoperative magnetic resonance imaging predict the cell lineages of nonfunctioning pituitary neuroendocrine tumors.Neuroradiology · 2025Article
- Non-recurrent mutations and copy number changes predominate pituitary adenoma genomes.European journal of endocrinology · 2025Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically nonfunctioning pituitary adenomas (NFAs) may be hormonally inactive tumors of differentiated cells, mainly not only gonadotroph adenomas (GAs) but also silent corticotroph adenomas (SCAs) and other differentiated silent adenomas. Recently, the use of transcription factors has been recommended to confirm cytodiffererentiation of these neoplasms. Our objective was to assess the clinical significance of the new classification system using transcription factors. Five hundred sixteen consecutive NFAs were studied retrospectively. They were initially classified based on hormone immunohistochemistry as follows: 119 hormone-negative adenomas (23.1 %), 300 GAs (58.1 %), 51 SCAs (9.9 %), and 46 other silent adenomas. The 119 hormone-negative adenomas were further evaluated for expression of transcription factors including steroidogenic factor-1 (SF-1), estrogen receptor-α (ERα), pituitary-specific transcription factor 1 (Pit-1), and t-box transcription factor (Tpit). One hundred thirteen of 119 (95 %) hormone-negative adenomas showed mutually exclusive lineage-specific differentiation as gonadotrophs (SF-1 positive), corticotrophs (Tpit positive), or somatotrophs/mammosomatotrophs/lactotrophs/thyrotrophs (Pit-1 positive) in 79 cases (66.4 %), 32 cases (26.9 %), and 2 cases, respectively. The 32 ACTH-negative and Tpit-positive adenomas had higher pro-opiomelanocortin mRNA expression levels compared with GAs (P = 0.0001) on quantitative real-time PCR. They showed a female preponderance (P < 0.0001) and were more frequently giant adenomas (P = 0.0028) associated with marked cavernous sinus invasion (P < 0.0001) compared with GAs. These clinical features were identical to those of the 51 ACTH-positive SCAs. Our results justify the complementary role of transcription factors in the precise classification of NFAs that can more accurately characterize biological behavior. Our data suggest that more than one quarter of hormone-negative adenomas are SCAs that share distinct clinicopathological features with ACTH-expressing SCAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.